Clinical trials: B-cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma, B-cell Malignancies
A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
The purpose of this study is to test the safety and tolerability of BG-T0920 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in…
- Trial name
- NCT07887646
- Testing
- BG-T0920
- Volunteers
- 70 people
- Sponsor
- BeOne Medicines
Diffuse Large B-Cell Lymphoma
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
This is a multicenter, single-arm, prospective study evaluating the efficacy and safety of polatuzumab vedotin and rituximab combined with a reduced-dose regimen of cyclophosphamide, doxorubicin and prednisone (Pola-R-miniCHP) as…
- Trial name
- NCT07908888
- Testing
- Polatuzumab Vedotin, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 26 people
- Sponsor
- The First Hospital of Jilin University
Diffuse Large B-cell Lymphoma
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in size, or have come…
- Trial name
- EPCORE DLBCL-1 (NCT04628494)
- Testing
- Epcoritamab, Investigator's Choice Chemotherapy
- Where
- 186 sites in United States, Australia and 22 more
- Volunteers
- 483 people
- Sponsor
- Genmab
Lymphoma
Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients with relapsed…
- Trial name
- NCT00002880
- Testing
- Etoposide phosphate
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00031642
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Nebraska
Marginal Zone B-cell Lymphoma
Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Splenic Marginal Zone Lymphoma (SMZL) is a well-defined low-grade B-cell lymphoma,considered as a rare neoplasm accounting for about 2% of all non-Hodgkin's lymphomas (NHL) and represents for most cases of otherwise…
- Trial name
- NCT02853370
- Testing
- Bendamustine and Rituximab
- Where
- 30 sites in France, Italy
- Volunteers
- 78 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Patients eligible for the study will receive R-DA-EDOCH as the induction therapy and be evaluated by PET CT after the fourth cycle.
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma
- Trial name
- NCT03837873
- Testing
- Rituximab, Etoposide, Vincristine
- Where
- 6 sites in China
- Volunteers
- 118 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Diffuse Large B Cell Lymphoma
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The purpose of this study is to investigate efficacy and safety of Lenalidomide in combination with R-GemOx as first-line treatment of elderly patients with Diffuse large B cell lymphoma.
- Trial name
- NCT04432402
- Testing
- Lenalidomide
- Where
- China
- Volunteers
- 124 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Acute Biphenotypic Leukemia, Acute Leukemia
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
This phase II trial tests how well removing CD45RA positive naive T cells works to prevent graft versus host disease in older patients undergoing standard of care allogeneic hematopoietic stem cell transplantation for the…
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
- Trial name
- NCT07819396
- Testing
- Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Fred Hutchinson Cancer Center
Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
The purpose of this study is to evaluate the safety and tolerability of MT-3724 in subjects with relapsed or refractory B-Cell NHL or relapsed and refractory CLL (Part 1 only) and relapsed and refractory DLBCL (Part 2 and Part…
- Conditions
- Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- MT-3724NHL001 (NCT02361346)
- Testing
- MT-3724 Phase 1, MT-3724 Phase 2
- Where
- 41 sites in United States, Belarus and 8 more
- Volunteers
- 38 people
- Sponsor
- Molecular Templates, Inc.
Non-Hodgkin's Lymphoma
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL)…
- Trial name
- NCT00312845
- Testing
- Bortezomib + Rituximab, Rituximab
- Where
- 206 sites in United States, Argentina and 30 more
- Volunteers
- 676 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy with or without glofitamab for the treatment of patients with untreated large B-cell lymphoma that grows and spreads…
- Conditions
- Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT04231877
- Testing
- Polatuzumab Vedotin, Rituximab, Prednisone
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Washington
Hematologic Malignancy
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
The goal of this clinical research study is to learn if fludarabine, cytarabine (ARA-C), and erwinase (also known as asparaginase [erwinia]) in combination can help to control relapsed or refractory hematologic malignancies.
- Trial name
- NCT02718755
- Testing
- Fludarabine, Cytarabine, Erwinase
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapy, Diffuse Large B-Cell Lymphoma (DLBCL), Nos
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Annual incidence increases with age and achieves more than 30 per 100 000 patients 65 years old or over.
- Conditions
- Chemotherapy, Diffuse Large B-Cell Lymphoma (DLBCL), Nos, Elderly
- Trial name
- Relyage (NCT04113226)
- Testing
- Rituximab, Lenalidomide 20 MG, Comprehensive Geriatric Assessment (CGA)
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Diffuse Large B-Cell Lymphoma (DLBCL)
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
This is a prospective, open-label, single-arm, single-center, Phase II clinical study designed to evaluate the efficacy and safety of Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab…
- Trial name
- Pola-ZRCHP (NCT07608978)
- Testing
- POLA-R-CHP+Zanubrutinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Trial name
- NCT01075321
- Testing
- everolimus, lenalidomide, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Mayo Clinic
Diffuse Large B-cell Lymphoma
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.
- Trial name
- NCT06503263
- Testing
- Zanubrutinib plus Lenalidomide as Maintenance Therapy
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Navy General Hospital, Beijing
Lymphoma
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of…
- Trial name
- NCT00005985
- Testing
- filgrastim, carmustine, cyclophosphamide
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02851589
- Testing
- PCAR-019 (anti-CD19 CAR-T cells)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
CAR-T Followed by Bispecific Antibodies
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells.
- Trial name
- NCT04889716
- Testing
- mosunetuzumab, glofitamab, obinutuzumab
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.